Celyad Oncology SA announced that on March 1, 2022, the company was informed via e-mail communication from the U.S. Food and Drug Administration that the CYAD-101-002 (KEYNOTE-B79) Phase 1b trial has been placed on clinical hold due to insufficient information to assess risk to study subjects. As previously disclosed, on February 28, 2022, the company announced that it was voluntarily pausing the CYAD-101-002 trial to investigate reports of two fatalities in the study.